Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Compugen Ltd. stock logo
CGEN
Compugen
$1.43
+1.4%
$1.55
$1.13
$2.66
$127.61M2.58387,407 shs174,240 shs
Genelux Corporation stock logo
GNLX
Genelux
$3.37
+1.2%
$3.33
$1.95
$5.89
$127.30M-0.32177,563 shs114,609 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.64
+5.8%
$1.52
$0.96
$3.10
$130.76M-0.23829,754 shs708,495 shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$1.35
-2.9%
$1.32
$1.04
$4.40
$31.47M1.1355,886 shs241,842 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Compugen Ltd. stock logo
CGEN
Compugen
0.00%-1.40%-4.73%-22.95%-32.86%
Genelux Corporation stock logo
GNLX
Genelux
0.00%-10.96%-5.13%+29.57%+53.46%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
0.00%-3.13%+6.90%-3.13%+64.16%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
0.00%+17.80%+25.23%-31.19%+138,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Compugen Ltd. stock logo
CGEN
Compugen
2.4567 of 5 stars
3.55.00.00.02.50.00.0
Genelux Corporation stock logo
GNLX
Genelux
1.1851 of 5 stars
3.50.00.00.03.20.00.0
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.3153 of 5 stars
3.52.00.00.03.21.71.9
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$4.00179.72% Upside
Genelux Corporation stock logo
GNLX
Genelux
3.00
Buy$20.33503.36% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00814.63% Upside
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest RNTX, CGEN, GNLX, and PLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
7/23/2025
Genelux Corporation stock logo
GNLX
Genelux
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Compugen Ltd. stock logo
CGEN
Compugen
$27.86M4.58N/AN/A$0.62 per share2.31
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/A$0.76 per shareN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$61.95M2.11$0.09 per share17.80$0.47 per share3.49
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/A$0.43 per share3.11$0.43 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Compugen Ltd. stock logo
CGEN
Compugen
-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%11/11/2025 (Estimated)
Genelux Corporation stock logo
GNLX
Genelux
-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.07N/A5.29N/A-21.03%-30.89%-11.74%N/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/A

Latest RNTX, CGEN, GNLX, and PLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$0.22-$0.28-$0.06-$0.28N/AN/A
8/7/2025Q2 2025
Genelux Corporation stock logo
GNLX
Genelux
-$0.22-$0.20+$0.02-$0.20N/AN/A
8/6/2025Q2 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Compugen Ltd. stock logo
CGEN
Compugen
N/A
4.74
4.74
Genelux Corporation stock logo
GNLX
Genelux
N/A
4.18
4.18
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/A
0.86
0.86

Institutional Ownership

CompanyInstitutional Ownership
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Genelux Corporation stock logo
GNLX
Genelux
37.33%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
90.89%

Insider Ownership

CompanyInsider Ownership
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
Genelux Corporation stock logo
GNLX
Genelux
8.80%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
Genelux Corporation stock logo
GNLX
Genelux
1037.77 million34.45 millionNot Optionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.73 million69.00 millionOptionable
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
923.31 million22.12 millionN/A

Recent News About These Companies

RNTX - Rein Therapeutics Inc Dividends - Morningstar
RNTX Rein Therapeutics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Compugen stock logo

Compugen NASDAQ:CGEN

$1.43 +0.02 (+1.42%)
Closing price 04:00 PM Eastern
Extended Trading
$1.41 -0.02 (-1.40%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Genelux stock logo

Genelux NASDAQ:GNLX

$3.37 +0.04 (+1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$3.50 +0.14 (+4.01%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.64 +0.09 (+5.81%)
Closing price 04:00 PM Eastern
Extended Trading
$1.64 0.00 (0.00%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$1.35 -0.04 (-2.88%)
As of 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.